Introduction
Chlamydia spp. are important human pathogens. Chlamydia trachomatis is the most frequent sexually transmitted infection in the United States, responsible for over three million cases of cervicitis and urethritis per year. 1 Chlamydia pneumoniae is a frequent cause of community-acquired respiratory tract infection including pneumonia and bronchitis in adults and children.
2, 3 Quinolones have attracted interest as potential therapy for both sexually transmitted infections and community-acquired respiratory tract infections because they are active against a wide range of pathogens responsible for these diseases. Ofloxacin is currently recommended by the Centers for Disease Control as an alternative regimen for the treatment of genital C. trachomatis infections in adults. 1 We previously reported that several quinolones, including ofloxacin, levofloxacin, grepafloxcin, sparfloxacin, trovafloxacin and moxifloxacin have significant activity against C. pneumoniae in vitro. [4] [5] [6] [7] We tested a new 8-methoxyquinolone, gatifloxacin, for activity against C. trachomatis and C. pneumoniae in comparison with ofloxacin and erythromycin. Susceptibility testing of C. trachomatis and C. pneumoniae was performed in cell culture using HEp-2 cells grown in 96-well microtiter plates. 7 Each well was inoculated with 0.1 mL of the test strain diluted to yield 10 3 to 10 4 inclusionforming units (IFU) per mL, centrifuged at 1700g for 1 h and incubated at 35°C for 1 h. Wells were then aspirated and overlaid with 0.2 mL of medium containing 1 mg/L of cycloheximide and serial two-fold dilutions of the test drug. After incubation at 35°C for 72 h, cultures were fixed and stained for inclusions with fluorescein-conjugated antibody to the lipopolysaccharide genus antigen (Pathfinder, Kallestad Diagnostics, Chaska, MN, USA). The MIC was the lowest antibiotic concentration at which no inclusions were seen. The minimal bactericidal concentration (MBC)
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The MICs and MBCs for all five strains of C. trachomatis were 0.25 mg/L of gatifloxacin, 0.125 mg/L of ofloxacin and 0.03 mg/L of erythromycin. The MICs and MBCs for C. pneumoniae are given in the Table. Gatifloxacin was slightly less active against C. trachomatis, and slightly more active against C. pneumoniae than ofloxacin but less active than erythromycin against both species The MICs of gatifloxacin against C. pneumoniae were very consistent from strain to strain, especially in view of the wide geographic distribution of the isolates tested. Data on the activity of gatifloxacin against Chlamydia spp. are limited. Miyashita et al. 8 tested gatifloxacin against three strains of C. trachomatis, five strains of C. pneumoniae, including TW 183 and AR 39 and two strains of Chlamydia psittaci. The MICs for all three species ranged from 0.063 to 0.125 mg/L. The MICs for C. pneumoniae TW 183 and AR39 were 0.063 mg/L, which is four-fold more active than our results with these strains. This difference may be within the standard error of the test. They also tested 25 recent clinical isolates and the MIC 90 and MBC 90 were 0.125 mg/L, which is not significantly different from our results with American clinical isolates. The MIC 90 and MBC 90 of ofloxacin against C. pneumoniae were 0.5 and 1 mg/L, respectively, which are almost exactly the values we found (MIC 90 and MBC 90 0.5 mg/L). Miyashita et al. 8 also evaluated the efficacy of treatment with gatifloxacin and other antibiotics on survival in a mouse model of C. psittaci pneumonia. The survival of mice treated with 5 mg/kg of gatifloxacin was s i g n i ficantly higher than that seen with ofloxacin. Wise et al. 9 tested gatifloxacin against three strains of C. trachomatis and C. pneumoniae TW-183. The MICs and MBCs ranged from 0.06 to 0.12 mg/L, which was two-to four-fold more active than we found for C. trachomatis and TW-183.
The 1998 Guidelines for the Treatment of Sexually Transmitted Diseases lists ofloxacin as an alternative regimen for the treatment of uncomplicated genital C. trachomatis infection in adolescents and adults. 1 Ofloxacin is similar in efficacy to doxycycline and azithromycin, but is more expensive and offers no advantage with regard to dosing and the length of treatment.
1 Based on its in-vitro activity and pharmacokinetics 10 , gatifloxacin should have equivalent efficacy to ofloxacin for treatment of C. trachomatis infections.
There are no published studies that have assessed the efficacy of any quinolone for the treatment of C. pneumoniae infection that have utilized culture. 4, 5 The diagnosis was based on serology alone, thus microbiological efficacy could not be assessed. We treated three patients with culture documented C. pneumoniae infection (bronchitis and pneumonia) with grepafloxacin. Although grepafloxacin has an MIC 90 and MBC 90 of 0.5 mg/L against C. pneumoniae, two of three patients remained culture-positive and symptomatic despite 2 weeks of treatment with the drug. 7 Prospective studies of gatifloxacin for the treatment of genital chlamydia infections and community-acquired pneumonia utilizing culture of C. trachomatis and C. pneumoniae will determine the role of gatifloxacin in the treatment of these infections. 
